Merck shelves study of cholesterol drug

Saying it had the wrong patient population, Merck has discontinued its ACHIEVE imaging study for its cholesterol drug MK-0524A. Its steering committee recommended a new imaging study that included a "more appropriate patient population." The ACHIEVE trial was intended to gauge the drug's impact on the thickness of artery walls.

Merck emphasized that the decision to discontinue the trial was not related to a recent Not Approvable letter from the FDA and that all other studies would proceed as planned. The FDA turned thumb's down on MK-0524A last April. The drug is a combination of the B vitamin niacin and the drug laropiprant.

- here's the release
- read the report from Hemscott

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."